Bretton Capital Management, an investment management company, released the “Bretton Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. Bretton Fund returned 1.44% in Q4 2025 compared to 2.66% for the S&P 500 Index. In 2025, the Fund returned 11.58% compared to 17.88% for the Index. Although the market fluctuates daily between excitement and concern regarding a potential bubble in artificial intelligence, the firm views the overall market as not in bubble territory at this stage but is modestly elevated. Given the Fund’s long-term perspective, it is acceptable to reduce more speculative elements of the AI boom, which might resemble a bubble, even if this leads to a temporary lag during strong market phases. The Fund is focusing on areas of value that will provide good returns over the long term. Please review the Fund’s top five holdings to gain insights into their key selections for 2025.
In its fourth-quarter 2025 investor letter, Bretton Fund highlighted stocks like Revvity, Inc. (NYSE:RVTY). Revvity, Inc. (NYSE:RVTY) is an American company that provides health sciences solutions, technologies, and services. On March 04, 2026, Revvity, Inc. (NYSE:RVTY) stock closed at $98.49 per share. One-month return of Revvity, Inc. (NYSE:RVTY) was -1.03%, and its shares lost 13.00% over the past 52 weeks. Revvity, Inc. (NYSE:RVTY) has a market capitalization of $11.166 billion.
Bretton Fund stated the following regarding Revvity, Inc. (NYSE:RVTY) in its fourth quarter 2025 investor letter:
“We invested in the former PerkinElmer in the wake of Covid. In many ways we are in a new golden age for medicine—the growth of biologics and peptides, new frontiers in personalized medicine, AI to identify actionable therapies, mRNA to deliver them—and Revvity, Inc. (NYSE:RVTY), which makes the consumables used in both research facilities and customer-facing diagnostics, seemed like a good platform. Unfortunately, management spent its Covid testing windfall on overpriced acquisitions while divesting its cash-generative but less exciting food testing division, and then was left flat-footed when pharma research spending stalled and the FDA dramatically reduced science spending. Our overall return was -28.5%, or a -5.90% IRR, but the most painful loss was our opportunity cost.”
Revvity, Inc. (NYSE:RVTY) is not on our list of 40 Most Popular Stocks Among Hedge Funds. According to our database, 35 hedge fund portfolios held Revvity, Inc. (NYSE:RVTY) at the end of the fourth quarter, up from 22 in the previous quarter. While we acknowledge the risk and potential of Revvity, Inc. (NYSE:RVTY) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Revvity, Inc. (NYSE:RVTY) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Revvity, Inc. (NYSE:RVTY) and shared Diamond Hill Mid Cap Strategy’s views on the company. In addition, please check out our hedge fund investor letters Q4 2025 page for more investor letters from hedge funds and other leading investors.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. This article is originally published at Insider Monkey.
